Decision and Details
Responses to inquiries
Fair disclosure of information to shareholders, investors and other parties, avoidance of the risk of causing confusion in medical settings, and compliance with business confidentiality obligations and insider information controls
| Item | Details |
|---|---|
| Matter Covered | Responses to inquiries |
| Decision Date | 4 September 2026 (disclosure date) |
| Implementation Date | Sales of Telomelysin injection began on 21 August 2026 (actual); the official announcement of inclusion in TOPIX is scheduled for October 2026 |
| Quantity / scale | TOPIX inclusion requirements: an annual trading value turnover ratio of at least 0.2 and a cumulative free-float market capitalization ratio within the top 96% |
| Reason | Fair disclosure of information to shareholders, investors and other parties, avoidance of the risk of causing confusion in medical settings, and compliance with business confidentiality obligations and insider information controls |
| Related previous disclosures | March 2026 shareholders’ meeting; August 2026 earnings briefing (title: Not disclosed) |
| Future plans | The company plans to provide another announcement when the Tokyo Stock Exchange announces its inclusion in TOPIX in October 2026. Regarding the adoption status of Telomelysin injection, it will advise medical institutions to confirm the status through specialist physicians. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company cited the need for fair disclosure of information to shareholders, investors and other parties, to avoid confusion caused by inquiries to the Tokyo Stock Exchange and financial institutions with which it conducts transactions, to avoid the risk of causing confusion in medical settings, and to comply with its business confidentiality obligations and insider information controls.